Results 201 to 210 of about 94,016 (287)

Patterns in Prescribing and Dispensing Influenza Antivirals Among Adults With Influenza Presenting to Urgent Care and Emergency Department Settings: VISION Network, 2023-2024. [PDF]

Clin Infect Dis
Adams K, Garg S, Tartof SY, Irving SA, DeSilva MB, Klein NP, Natarajan K, Dascomb K, Grannis SJ, Ong TC, Salas SB, Sy LS, Lewin B, Qian L, Naleway AL, Koppolu PD, McEvoy CE, Akinsete O, Essien I, Fireman B, Zerbo O, Jacobson KB, Timbol J, Neelam V, Reeves EL, Dickerson M, Ray C, Link-Gelles R, Mak J, Ball SW, O'Reilly M, Olsen SJ, Tenforde MW.   +32 more
europepmc   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Prevalence of herpes simplex virus 1 and 2 in culture-negative suppurative keratitis using polymerase chain reaction - A pilot study. [PDF]

Indian J Ophthalmol
Rajasekaran NM, Krishna TS, Amritanand A, Korah S, Abraham AM, Mammen S, Michael J, Ramadoss B, Samuel P, Kuriakose T, Paul P.   +10 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Strategic Preparedness of Broad-Spectrum Antivirals for Rapid Response Towards Next Pandemics. [PDF]

Small Sci
N SR, Jin GW, Choy JH.
europepmc   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

Viral eye: Emerging insights into corneal and ocular surface viral infections. [PDF]

World J Virol
Zeppieri M, Capobianco M, Avitabile A, Visalli F, Mazzotta C, Musa M, Giglio R, Tognetto D, Gagliano C, Cappellani F.   +9 more
europepmc   +1 more source

Learning Strategies from Nature's Blueprint to Cyclic Carbonate Synthesis

ChemSusChem, Volume 18, Issue 6, March 15, 2025.
The development of sustainable synthetic methods for cyclic carbonates draws inspiration from nature, focusing on eco‐friendly processes and renewable resources like CO2 and biomass. This review explore various CO2 activation mechanisms, green chemistry principles, and green catalysts.
Erika Saccullo, Vincenzo Patamia, Chiara Zagni, Antonio Rescifina, Giuseppe Floresta   +4 more
wiley   +1 more source

Letermovir shows antiviral and neuroprotective effects in differentiating neurons and cerebral organoids mimicking human developing brain. [PDF]

Cell Mol Life Sci
Mercorelli B, Poli E, Pianezzola A, Faggin E, Arav-Boger R, Palù G, Loregian A, Trevisan M.   +7 more
europepmc   +1 more source

Superior Intracellular Detection of Cytokines, Transcription Factors, and Phosphoproteins by CyTOF Compared With Fluorescent Cytometry

Cytometry Part A, EarlyView.
ABSTRACT Unraveling biological complexity, such as immune subset distribution in infectious disease(s), autoimmunity, or tumor heterogeneity, requires technologies capable of single‐cell proteomic analysis such as flow cytometry. Surface phenotyping alone is often insufficient, as interrogating functional capacity is required to determine cellular ...
Michael J. Cohen, Erika L. Smith‐Mahoney, Madison Bailey, Ling Wang, Lauren J. Tracey, Laura Polanco, David King, Christina Loh, Amedeo J. Cappione III, Anna C. Belkina, Jennifer E. Snyder‐Cappione   +10 more
wiley   +1 more source